Food and Drug Administration (FDA) for weight loss as early as the end of the year 1
What changes is how youre eating, digesting, and sweating
The trial program has evolved from glycemic-safety and outcomes studies in T2D (the LEADER, SUSTAIN-6, REWIND, EXSCEL, and PIONEER 6 era [10][13], [19]), to outcomes trials in expanded populations including obesity without diabetes (SELECT [3]), HFpEF with obesity (SUMMIT [5], with a companion semaglutide program in STEP-HFpEF [20], [21]), CKD (FLOW [22]), and an active-comparator setting (SURPASS-CVOT [6])
RELATED: Ozempic for weight loss Key differences between compounded semaglutide and FDA-approved brands Wegovy and Ozempic contain the same active ingredient, semaglutide, a GLP-1 receptor agonist that is FDA approved for weight management and Type 2 diabetes, respectively
& George, C